Signal Diagnostics agrees to pay $20.5M to settle COVID-19 testing overpayment claims
Signal Diagnostics LLC has agreed to pay the United States $20.5 million to resolve allegations that it violated the False Claims Act by knowingly retaining federal overpayments and improperly avoiding its obligation to repay funds received for COVID-19 testing of patients who had health insurance, the Justice Department announced.
TL;DR
- Signal Diagnostics LLC will pay $20.5 million to the United States.
- The payment settles allegations of violating the False Claims Act.
- The company is accused of knowingly retaining federal overpayments.
- Signal Diagnostics allegedly failed to repay funds for COVID-19 testing of insured patients.